No Data
No Data
Repare Therapeutics To Host Webcast To Report Data From The Lunresertib And Camonsertib Combination Phase 1 MYTHIC Clinical Trial On Thursday, December 12 At 4:30 P.m. ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Express News | Repare Therapeutics Announces Agreement With the US National Cancer Institute to Advance the Development of Camonsertib
Morgan Stanley Maintains Repare Therapeutics(RPTX.US) With Hold Rating, Maintains Target Price $8
Morgan Stanley Sticks to Their Hold Rating for Repare Therapeutics (RPTX)
Stifel Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $9
No Data